Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Efficacy Data in Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website
Median Survival Time - an overview | ScienceDirect Topics
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab | Journal for ImmunoTherapy of Cancer | Full Text
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters | PLOS ONE
A Overall survival (OS) for the entire cohort. The median OS is... | Download Scientific Diagram
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... | Download Scientific Diagram
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Overall survival (OS) analyses. Case numbers, median OS and P-values... | Download Scientific Diagram
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Overall survival. Median OS was 13 months (95%Cl 9–16). | Download Scientific Diagram
Kaplan-Meier plot of median Os (interim analysis) (n=90).... | Download Scientific Diagram
Effectiveness & Safety of TECENTRIQ® (atezolizumab) for ES-SCLC
Prognostic model for overall survival (OS). The median OS for the good,... | Download Scientific Diagram
Treatment Outcomes for Adult Patients With R/R B-cell ALL
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
A Overall survival (OS) for the entire cohort. The median OS is... | Download Scientific Diagram
Efficacy I PLUVICTO
BLINCYTO® Adult Efficacy | BLINCYTO® (blinatumomab)
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
Cemiplimab prolongs OS in NSCLC with high PD-L1 expression
